Fladgate advises Morria Biopharmaceuticals on trading of American Depositary Shares


Our team: Avram Kelman


Fladgate LLP has advised Morria Biopharmaceuticals Plc (Morria) on the commencement of trading of Morria’s American Depositary Shares, representing its ordinary shares, on the OTC Bulletin Board in the United States.

Morria is an emerging growth biopharmaceutical company focused on the development of first-in-class drugs, multi-functional non-steroidal, synthetic anti-inflammatory drugs. The commencement of trading of Morria’s securities in the United States is an important step for the company, positioning them for broad and diversified investor exposure.

Fladgate corporate partner Avram Kelman advised Morria along with Mintz Levin in New York.

View by author:


Would you like to hear more?